We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Automated Extraction System Produces High Quality RNA-free DNA

By LabMedica International staff writers
Posted on 18 Oct 2015
A state-of-the-art precipitation-based system completely automates the DNA extraction process from primary tube sampling to final DNA elution into storage tubes.

The AutoGen (Holliston, MA, USA), FlexSTAR+ platform is a system that produces RNA-free DNA in an extremely user-friendly environment.

The FlexSTAR+ system includes protocols for fresh or frozen blood samples of 1 to 2 milliliters, 3 to 5 milliliters, and 6 to 10 milliliters. More...
The instrument can draw samples from a variety of primary tube sizes, running up to 30 samples in a batch. It reads and records barcodes on primary tubes, has an internal barcode scanner to verify sample input and DNA output positions, provides liquid level detection for accurate pipetting, and delivers its final elution in SBS (sterile barrier system)-type storage tubes of the user’s choosing.

FlexSTAR+ features sample tracking and reporting software that verifies work lists from LIM (laboratory information management) input, creates a map of sample and DNA positions, tracks samples through the extraction process, and sends final reports back to LIMs. The software also sends an email or text alert to notify the operator when the run is complete.

The extraction process operates with Qiagen (Venlo, The Netherlands) FlexiGene chemistry. This precipitation-based procedure yields cleaner, longer-stranded DNA than does magnetic bead-based methods. Furthermore, since the Qiagen DNA extraction process begins with the collection of the white cell nuclei pellet, it eliminates RNA contamination that can occur with magnetic bead technology and other technologies that produce total nucleic acid instead of pure genomic DNA.

“Biorepositories, genetic treatment and cancer centers, and specialty diagnostic labs that currently are using Qiagen’s AutoPure solution for DNA extraction will be familiar and comfortable with precipitation technology,” said Bob Sullivan, president and CEO of AutoGen. “FlexSTAR+ is a logical step-up for them. In fact, it is a superior solution for any lab that wants to generate higher quality, higher yield genomic DNA with less work and errors and far less likelihood of RNA contamination, and that stands to benefit from the superior service for which AutoGen is known.”

Related Links:

AutoGen
Qiagen



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.